-
Posted by
Two Blokes Jul 10 -
Filed in
Stock
-
7 views
Rhythm Pharmaceuticals, Inc.'s IMCIVREE and new oral MC4R agonist, bivamelagon, show strong efficacy in rare obesity disorders, especially hypothalamic obesity (HO). HO represents a blockbuster market opportunity with minimal competition, as MC4R agonists address the root cause, unlike GLP-1s. Pipeline expansion, including oral and weekly MC4R agonists, positions Rhythm for long-term market dominance in rare obesity beyond 2040.
